Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 4/20 | 0.43 |
| ▸ | HRH1 | P35367 | 4/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898615 | 1.00 | GPR119 (0.48) | GPR119DPP4KCNH2HRH2HRH1 | |
| SCHEMBL2898041 | 0.91 | GPR119 (0.51) | GPR119KCNH2HRH2HRH1GPR183 | |
| SCHEMBL2898045 | 0.91 | GPR119 (0.51) | GPR119KCNH2HRH2HRH1GPR183 | |
| SCHEMBL2898032 | 0.89 | GPR119 (0.54) | GPR119DPP4KCNH2GPR183DPP8 | |
| SCHEMBL2898037 | 0.89 | GPR119 (0.54) | GPR119DPP4KCNH2GPR183DPP8 | |
| SCHEMBL2895407 | 0.87 | GPR119 (0.48) | GPR119DPP4KCNH2HRH2HRH1 | |
| SCHEMBL2895404 | 0.87 | GPR119 (0.48) | GPR119DPP4KCNH2HRH2HRH1 | |
| SCHEMBL2891463 | 0.86 | HRH2 (0.48) | GPR119KCNH2HRH2HRH1 | |
| SCHEMBL2891469 | 0.86 | HRH2 (0.48) | GPR119KCNH2HRH2HRH1 | |
| SCHEMBL19059062 | 0.85 | GPR119 (0.49) | GPR119KCNH2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | GPR119 1/4885DPP4 2/4885KCNH2 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.